T2 Biosystems Sponsored Session: Culture-independent Testing: A New Way to Hurdle Obstacles for Detection of Sepsis-causing Pathogens and Improve Patient Outcomes
Culture-independent tests may provide faster and more accurate results that are not hindered by the long wait involved in the current standard of care that relies on a positive blood culture result. T2 Biosystems’ Panels provide results directly from a whole blood sample, often before the second dose of antibiotics is delivered. Speakers discuss the limitation of the current standard of care in detecting sepsis-causing pathogens, the impact of T2Bacteria on transplant patients, and the clinical performance of the T2Resistance Panel RUO.
This session was originally presented in September 2021 as part of the 2021 Sepsis Alliance Summit.
Nurses, Advanced Practice Providers, Physicians, Emergency Responders, Pharmacists, Medical Technologists, Respiratory Therapists, Physical/ Occupational Therapist, Social Workers, Mental Health Professionals, Students, IT Professionals, Sepsis Survivors, Advocates, and more!
Sepsis Alliance gratefully acknowledges the support provided for this session by T2 Biosystems.
Aparna Ahuja, MD
Chief Medical Officer, T2 Biosystems
Aparna Ahuja, MD joined T2 Biosystems as Chief Medical Officer in January of 2021. Dr. Ahuja possesses extensive global experience in laboratory medicine and medical diagnostics. Most recently, she served as Worldwide Vice President, Medical Affairs at Becton Dickinson, where she was responsible for global medical leadership, setting and leading the strategy for medical affairs, clinical development, and key opinion leader engagement in support of new product development, lifecycle management, and compliance. Prior to Becton Dickinson, Dr. Ahuja held a variety of roles in clinical practice, research, and academia where she was focused on continuous improvement and innovation in diagnostics, stressing precision, and rapid turnaround times. A clinical pathologist by training, Dr. Ahuja completed multiple residencies emphasizing medical biochemistry, molecular biology, and laboratory medicine. She earned a Bachelor of Medicine, Bachelor of Surgery, completed her MD Residencies, and received her Postgraduate Diploma in Family Welfare, Child Health, and Hospital Management from Delhi University. A certified auditor with ISO 15189 (NABL) & CAP, Dr. Ahuja has successfully led and guided pathology laboratories through audits and inspections from CAP, ISO 15189, ANVISA, CDC, and the FDA. She is an active member of the American Association of Clinical Chemistry (AACC), College of American Pathologists (CAP), American Society of Microbiology (ASM), European Federation of Clinical Chemistry and Laboratory Medicine (EFLM), and serves as President of AACC New Jersey and as Vice-Chair of CLSI’s Expert Panel. As an ardent speaker, she presents at renowned International Laboratory Medicine Conferences and has many peer-reviewed publications to her credit.
George A Pankey MD, MACP
Director, Infectious Disease Research, Ochsner Health
George A. Pankey, MD is Director of Infectious Disease Research at Ochsner Clinic Foundation in New Orleans, Louisiana. He is also Clinical Professor of Medicine at Tulane University in New Orleans. Dr. Pankey created the Section of Infectious Diseases and the Infectious Disease Fellowship Training Program at Oschner Health. He served as Head and Program Director, respectively, of these programs for more than 20 years. Dr. Pankey has authored or co-authored 5 books, 30 book chapters, and more than 160 peer-reviewed journal articles. Of special interest to him are the areas of antimicrobial therapy and resistance. He is a member of the Editorial Board of Infectious Disease News. He received the Clinician Award of the Infectious Diseases Society of America and Mastership in the American College of Physicians.
Minh-Hong Nguyen, MD
Professor of Medicine, University of Pittsburgh
Dr. Nguyen's multiple research interests are medical mycology research, including projects on the mechanisms and clinical impact of antifungal drug resistance, and molecular pathogenesis of invasive Candida infections. Since 2016, she extended her interest in Mucorales genetics and epidemiology. In addition, her research focuses on antibiotic resistant (AMR) bacterial infections and antimicrobial stewardship research, including projects on evolution of tolerance/resistance and pathogenic mechanisms of carbapenem-resistant Enterobacteriaceae (CRE) and other Gram negative bacteria; the development of novel antibiotic treatment strategies based upon bacterial genetics and pharmacokinetic-pharmacodynamic (PK-PD) principles; the clinical and economic impact of AMR infections and antimicrobial stewardship interventions; and clinical trials of new antimicrobials and diagnostic tests. Dr. Nguyen's Transplant Infectious Diseases (TID) research includes projects on the role of the microbiome in infections and outcomes among transplant recipients, the impact of rectal CRE carriage on transplant patients' outcome, and clinical studies and trials on a wide range of opportunistic fungal, bacterial, and viral infections. She has published numerous papers on the optimal use of rapid, non-culture tests in diagnosing sepsis and other acute infections, and in antimicrobial stewardship interventions.
No continuing education credits are offered for this session.
The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.